Marinus Pharmaceuticals, Inc. provided revenue guidance for the fiscal year 2022. For the period, the company expects BARDA revenues in the range of $7 to $10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.38 USD | +6.15% | +6.15% | -87.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.30% | 71.41M | |
+38.51% | 728B | |
+33.05% | 603B | |
-6.23% | 360B | |
+18.78% | 332B | |
+1.35% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.19% | 164B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022